Equities research analysts expect Allena Pharmaceuticals Inc (NASDAQ:ALNA) to post ($0.53) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Allena Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.40) and the lowest estimate coming in at ($0.58). Allena Pharmaceuticals posted earnings of ($0.46) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 15.2%. The business is scheduled to report its next earnings report on Thursday, March 5th.
Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Allena Pharmaceuticals.
Allena Pharmaceuticals (NASDAQ:ALNA) last released its earnings results on Wednesday, November 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.08).
ALNA traded down $0.04 on Friday, hitting $1.91. 284,895 shares of the company were exchanged, compared to its average volume of 160,787. Allena Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $9.60. The company has a market cap of $44.82 million, a PE ratio of -1.11 and a beta of 1.65. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.96 and a current ratio of 3.96. The stock’s fifty day moving average is $3.45 and its 200-day moving average is $4.11.
A number of large investors have recently added to or reduced their stakes in the business. Millennium Management LLC raised its stake in Allena Pharmaceuticals by 48.8% in the third quarter. Millennium Management LLC now owns 484,625 shares of the company’s stock valued at $1,909,000 after buying an additional 158,908 shares during the period. Wedbush Securities Inc. raised its stake in Allena Pharmaceuticals by 66.6% in the third quarter. Wedbush Securities Inc. now owns 25,650 shares of the company’s stock valued at $101,000 after buying an additional 10,250 shares during the period. Susquehanna International Group LLP bought a new stake in Allena Pharmaceuticals in the second quarter valued at approximately $137,000. Jane Street Group LLC bought a new stake in Allena Pharmaceuticals in the second quarter valued at approximately $116,000. Finally, Paloma Partners Management Co bought a new stake in Allena Pharmaceuticals in the second quarter valued at approximately $212,000. Hedge funds and other institutional investors own 64.60% of the company’s stock.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Read More: Are FAANG stocks a good investment?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.